Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Finger-Prick test could speed up blood clot diagnosis

NCT ID NCT04737954

Diagnosis Sponsor: LumiraDx UK Limited Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new rapid D-dimer blood test (LumiraDx) in 679 people with symptoms of deep vein thrombosis or pulmonary embolism. The test uses a small blood sample from a finger prick or vein to quickly measure D-dimer levels, which can help rule out dangerous blood clots. Researchers compared the new test's accuracy to standard lab methods to see if it could be a reliable tool for faster diagnosis.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
LumiraDx point-of-care D-dimer assay
What this could lead to
If accurate, this could provide a faster, easier way to rule out dangerous blood clots in the legs or lungs, potentially reducing the need for hospital visits.
What could go wrong
This is a diagnostic accuracy study, not a treatment trial. The test may not be as reliable as standard lab methods, and results depend on proper use and patient selection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

679 people

The number who actually took part.

Started

Mar 2021

Finished

Sep 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

adult UK and German population as a representation of the wider European population.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Subject is greater or equal to 18 years of age Willing and able to provide written informed consent and comply with study procedures Symptoms of thromboembolic event Exclusion Criteria: Suspected Sinus Venous Thromboembolism / Cerebral Venous Sinus Thromboembolism End-stage renal failure on haemodialysis Current anticoagulant therapy (Fragmin, LMWH) within the last 30 days Patient has previously participated in this study Life expectancy documented as \<30 days Haemodynamically unstable (e.g. cardiogenic shock) Patients taking anticoagulant therapy (DOACS, Warfarin, Heparins etc) within the last 30 days Patient deemed medically unfit to participate

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Deep vein thrombosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

pulmonary embolism venous thromboembolism Venous Thrombosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Deep vein thrombosis Pulmonary embolism Venous thromboembolism

Contacts and locations

Locations

  • Addenbrookes Hospital

    Cambridge, United Kingdom

  • Epsom and St Helier Hospitals

    Epsom, United Kingdom

  • Glsagow Royal Infirmary

    Glasgow, United Kingdom

  • Homerton University Hospital NHS Foundation Trust

    London, United Kingdom

  • Manchester Royal Infirmary

    Manchester, United Kingdom

  • Queen Elizabeth University Hospital

    Glasgow, United Kingdom

  • Royal Infirmary of Edinburgh

    Edinburgh, United Kingdom

  • Royal London Hospital

    London, United Kingdom

  • South Warwickshire Foundation Trust

    Warwick, United Kingdom

  • St Georges Hospital

    London, United Kingdom

  • St Johns Hospital

    Livingston, United Kingdom

  • University College Hospital

    London, United Kingdom

  • Universitäres Herz- und Gefäßzentrum Hamburg

    Hamburg, 20246, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.